Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
The transaction, completed in
“We’re pleased to have collected the full amount of escrow funds from Saol, which together with our existing cash and cash flow from our marketed product, IXINITY, further strengthens our cash position as we make important progress in 2019 advancing two lead ADAPTIR bispecific antibody programs, APVO436 and APVO210, being evaluated for the treatment of acute myeloid leukemia and autoimmune disorders, respectively. Dosing in the APVO436 Phase 1 clinical study commenced recently and we anticipate beginning a Phase 1 clinical study of APVO210 in healthy volunteers this quarter,” said
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo’s outlook, financial performance or financial condition, Aptevo’s technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the
Senior Director, Investor Relations and Corporate Communications
206-859-6628 / JurchisonS@apvo.com
Source: Aptevo Therapeutics Inc.